Related Experiment Video

Updated: Jul 16, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Disrupting Skp2-cyclin A interaction with a blocking peptide induces selective cancer cell killing

Peng Ji1, Daqian Sun, Hongbo Wang

  • 1Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Room U-521, Bronx, NY 10461, USA.

Molecular Cancer Therapeutics
|February 20, 2007
PubMed

Insights

A novel peptide blocks Skp2-cyclin A interaction, inducing cancer cell death. This peptide shows promise as a cancer therapy target, especially when combined with other agents.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Skp2 (S-phase kinase-associated protein 2) is an oncoprotein frequently overexpressed in cancers.
  • Skp2 targets p27(Kip1) for degradation and interacts with cyclin A, protecting it from p27 inhibition.
  • Targeting Skp2 is a potential strategy for cancer therapy.

Purpose of the Study:

  • To investigate the role of Skp2-cyclin A interaction in cancer cell survival.
  • To develop a peptide inhibitor targeting the Skp2-cyclin A interaction.
  • To evaluate the therapeutic potential of this peptide in cancer models.

Main Methods:

  • Designed an 18-residue peptide to block Skp2-cyclin A interaction.
  • Assessed peptide efficacy in vitro using kinase assays with p27.
  • Administered peptide via transmembrane delivery to cancer cell lines.
  • Investigated synergistic effects with an E2F1-derived peptide.
  • Correlated peptide IC50 with Skp2 abundance.

Main Results:

  • The Skp2-cyclin A blocking peptide inhibited cyclin A/Cdk2 activity in a p27-dependent manner.
  • Transmembrane delivery of the peptide induced cell death in multiple cancer cell lines.
  • The peptide synergized with an E2F1-derived peptide to enhance cancer cell killing.
  • Therapeutic efficacy correlated with Skp2 protein levels in cancer cells.

Conclusions:

  • Skp2-cyclin A interaction is crucial for cancer cell survival.
  • The developed peptide inhibitor represents a promising new avenue for cancer drug discovery.
  • Targeting Skp2-cyclin A interaction offers a viable therapeutic strategy.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...